Jonathan Chang
Stock Analyst at Leerink Partners
(4.14)
# 1,578
Out of 5,020 analysts
553
Total ratings
37.9%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $3.76 | +139.36% | 1 | Jul 13, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $3.91 | - | 7 | Jun 2, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $11 | $1.04 | +957.69% | 1 | Apr 27, 2026 | |
| REPL Replimune Group | Downgraded: Hold | $13 → $2 | $13.24 | -84.89% | 48 | Apr 13, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $205.26 | -28.38% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Reiterated: Buy | $24 → $37 | $31.43 | +17.72% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $8.78 | +93.62% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $19.47 | +59.22% | 1 | Feb 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $10.71 | +86.74% | 51 | Jan 13, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $15.97 | +50.33% | 19 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $26.34 | +180.94% | 51 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $39 | $35.68 | +9.32% | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $1.22 | +391.80% | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $3.86 | n/a | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.11 → $0.09 | $0.038 | n/a | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $3.68 | n/a | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $30.29 | n/a | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $24.95 | n/a | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.015 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $958.91 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $47.29 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0003 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.98 | n/a | 1 | Jun 1, 2022 |
Whitehawk Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.76
Upside: +139.36%
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.91
Upside: -
Compass Therapeutics
Apr 27, 2026
Reiterated: Buy
Price Target: $11
Current: $1.04
Upside: +957.69%
Replimune Group
Apr 13, 2026
Downgraded: Hold
Price Target: $13 → $2
Current: $13.24
Upside: -84.89%
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $205.26
Upside: -28.38%
Nanobiotix
Apr 1, 2026
Reiterated: Buy
Price Target: $24 → $37
Current: $31.43
Upside: +17.72%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $8.78
Upside: +93.62%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $19.47
Upside: +59.22%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $10.71
Upside: +86.74%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $15.97
Upside: +50.33%
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $26.34
Upside: +180.94%
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $35.68
Upside: +9.32%
Oct 10, 2025
Reiterated: Hold
Price Target: $8 → $6
Current: $1.22
Upside: +391.80%
Aug 18, 2025
Reiterated: Buy
Price Target: $8 → $5
Current: $3.86
Upside: n/a
Aug 13, 2025
Reiterated: Hold
Price Target: $0.11 → $0.09
Current: $0.038
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $3.68
Upside: n/a
Aug 11, 2025
Reiterated: Buy
Price Target: $60
Current: $30.29
Upside: n/a
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $24.95
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.015
Upside: n/a
Jun 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $958.91
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $47.29
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0003
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: n/a
Current: $5.98
Upside: n/a